Synopsis
0
EU WC
0
VMF
0
Europe
0
Canada
0
Australia
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CEP/COS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Related Excipient Companies
EUROAPI
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Evonik
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Nanjing Well Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pfanstiehl
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Actylis
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Finar
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Chemicals
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Kerry
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Microlex e.U
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Nanjing Bold Chemical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Parenteral
Solubilizers
Topical
Emulsifying Agents
Film Formers & Plasticizers
Surfactant & Foaming Agents
Fillers, Diluents & Binders
Thickeners and Stabilizers
Rheology Modifiers
Coating Systems & Additives
Taste Masking
API Stability Enhancers
Controlled & Modified Release
Direct Compression
Co-Processed Excipients
Digital Content
DATA COMPILATION #PharmaFlow
NEWS #PharmaBuzz
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
35
PharmaCompass offers a list of Hyaluronidase API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Hyaluronidase manufacturer or Hyaluronidase supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Hyaluronidase manufacturer or Hyaluronidase supplier.
PharmaCompass also assists you with knowing the Hyaluronidase API Price utilized in the formulation of products. Hyaluronidase API Price is not always fixed or binding as the Hyaluronidase Price is obtained through a variety of data sources. The Hyaluronidase Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A 2,4-bis(1,3-benzodioxol-5-yl)-4-oxobutanoic acid manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of 2,4-bis(1,3-benzodioxol-5-yl)-4-oxobutanoic acid, including repackagers and relabelers. The FDA regulates 2,4-bis(1,3-benzodioxol-5-yl)-4-oxobutanoic acid manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. 2,4-bis(1,3-benzodioxol-5-yl)-4-oxobutanoic acid API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of 2,4-bis(1,3-benzodioxol-5-yl)-4-oxobutanoic acid manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A 2,4-bis(1,3-benzodioxol-5-yl)-4-oxobutanoic acid supplier is an individual or a company that provides 2,4-bis(1,3-benzodioxol-5-yl)-4-oxobutanoic acid active pharmaceutical ingredient (API) or 2,4-bis(1,3-benzodioxol-5-yl)-4-oxobutanoic acid finished formulations upon request. The 2,4-bis(1,3-benzodioxol-5-yl)-4-oxobutanoic acid suppliers may include 2,4-bis(1,3-benzodioxol-5-yl)-4-oxobutanoic acid API manufacturers, exporters, distributors and traders.
click here to find a list of 2,4-bis(1,3-benzodioxol-5-yl)-4-oxobutanoic acid suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A 2,4-bis(1,3-benzodioxol-5-yl)-4-oxobutanoic acid DMF (Drug Master File) is a document detailing the whole manufacturing process of 2,4-bis(1,3-benzodioxol-5-yl)-4-oxobutanoic acid active pharmaceutical ingredient (API) in detail. Different forms of 2,4-bis(1,3-benzodioxol-5-yl)-4-oxobutanoic acid DMFs exist exist since differing nations have different regulations, such as 2,4-bis(1,3-benzodioxol-5-yl)-4-oxobutanoic acid USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A 2,4-bis(1,3-benzodioxol-5-yl)-4-oxobutanoic acid DMF submitted to regulatory agencies in the US is known as a USDMF. 2,4-bis(1,3-benzodioxol-5-yl)-4-oxobutanoic acid USDMF includes data on 2,4-bis(1,3-benzodioxol-5-yl)-4-oxobutanoic acid's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The 2,4-bis(1,3-benzodioxol-5-yl)-4-oxobutanoic acid USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of 2,4-bis(1,3-benzodioxol-5-yl)-4-oxobutanoic acid suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The 2,4-bis(1,3-benzodioxol-5-yl)-4-oxobutanoic acid Drug Master File in Japan (2,4-bis(1,3-benzodioxol-5-yl)-4-oxobutanoic acid JDMF) empowers 2,4-bis(1,3-benzodioxol-5-yl)-4-oxobutanoic acid API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the 2,4-bis(1,3-benzodioxol-5-yl)-4-oxobutanoic acid JDMF during the approval evaluation for pharmaceutical products. At the time of 2,4-bis(1,3-benzodioxol-5-yl)-4-oxobutanoic acid JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of 2,4-bis(1,3-benzodioxol-5-yl)-4-oxobutanoic acid suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a 2,4-bis(1,3-benzodioxol-5-yl)-4-oxobutanoic acid Drug Master File in Korea (2,4-bis(1,3-benzodioxol-5-yl)-4-oxobutanoic acid KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of 2,4-bis(1,3-benzodioxol-5-yl)-4-oxobutanoic acid. The MFDS reviews the 2,4-bis(1,3-benzodioxol-5-yl)-4-oxobutanoic acid KDMF as part of the drug registration process and uses the information provided in the 2,4-bis(1,3-benzodioxol-5-yl)-4-oxobutanoic acid KDMF to evaluate the safety and efficacy of the drug.
After submitting a 2,4-bis(1,3-benzodioxol-5-yl)-4-oxobutanoic acid KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their 2,4-bis(1,3-benzodioxol-5-yl)-4-oxobutanoic acid API can apply through the Korea Drug Master File (KDMF).
click here to find a list of 2,4-bis(1,3-benzodioxol-5-yl)-4-oxobutanoic acid suppliers with KDMF on PharmaCompass.
A 2,4-bis(1,3-benzodioxol-5-yl)-4-oxobutanoic acid CEP of the European Pharmacopoeia monograph is often referred to as a 2,4-bis(1,3-benzodioxol-5-yl)-4-oxobutanoic acid Certificate of Suitability (COS). The purpose of a 2,4-bis(1,3-benzodioxol-5-yl)-4-oxobutanoic acid CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of 2,4-bis(1,3-benzodioxol-5-yl)-4-oxobutanoic acid EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of 2,4-bis(1,3-benzodioxol-5-yl)-4-oxobutanoic acid to their clients by showing that a 2,4-bis(1,3-benzodioxol-5-yl)-4-oxobutanoic acid CEP has been issued for it. The manufacturer submits a 2,4-bis(1,3-benzodioxol-5-yl)-4-oxobutanoic acid CEP (COS) as part of the market authorization procedure, and it takes on the role of a 2,4-bis(1,3-benzodioxol-5-yl)-4-oxobutanoic acid CEP holder for the record. Additionally, the data presented in the 2,4-bis(1,3-benzodioxol-5-yl)-4-oxobutanoic acid CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the 2,4-bis(1,3-benzodioxol-5-yl)-4-oxobutanoic acid DMF.
A 2,4-bis(1,3-benzodioxol-5-yl)-4-oxobutanoic acid CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. 2,4-bis(1,3-benzodioxol-5-yl)-4-oxobutanoic acid CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of 2,4-bis(1,3-benzodioxol-5-yl)-4-oxobutanoic acid suppliers with CEP (COS) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing 2,4-bis(1,3-benzodioxol-5-yl)-4-oxobutanoic acid as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for 2,4-bis(1,3-benzodioxol-5-yl)-4-oxobutanoic acid API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture 2,4-bis(1,3-benzodioxol-5-yl)-4-oxobutanoic acid as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain 2,4-bis(1,3-benzodioxol-5-yl)-4-oxobutanoic acid and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a 2,4-bis(1,3-benzodioxol-5-yl)-4-oxobutanoic acid NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of 2,4-bis(1,3-benzodioxol-5-yl)-4-oxobutanoic acid suppliers with NDC on PharmaCompass.
2,4-bis(1,3-benzodioxol-5-yl)-4-oxobutanoic acid Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of 2,4-bis(1,3-benzodioxol-5-yl)-4-oxobutanoic acid GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right 2,4-bis(1,3-benzodioxol-5-yl)-4-oxobutanoic acid GMP manufacturer or 2,4-bis(1,3-benzodioxol-5-yl)-4-oxobutanoic acid GMP API supplier for your needs.
A 2,4-bis(1,3-benzodioxol-5-yl)-4-oxobutanoic acid CoA (Certificate of Analysis) is a formal document that attests to 2,4-bis(1,3-benzodioxol-5-yl)-4-oxobutanoic acid's compliance with 2,4-bis(1,3-benzodioxol-5-yl)-4-oxobutanoic acid specifications and serves as a tool for batch-level quality control.
2,4-bis(1,3-benzodioxol-5-yl)-4-oxobutanoic acid CoA mostly includes findings from lab analyses of a specific batch. For each 2,4-bis(1,3-benzodioxol-5-yl)-4-oxobutanoic acid CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
2,4-bis(1,3-benzodioxol-5-yl)-4-oxobutanoic acid may be tested according to a variety of international standards, such as European Pharmacopoeia (2,4-bis(1,3-benzodioxol-5-yl)-4-oxobutanoic acid EP), 2,4-bis(1,3-benzodioxol-5-yl)-4-oxobutanoic acid JP (Japanese Pharmacopeia) and the US Pharmacopoeia (2,4-bis(1,3-benzodioxol-5-yl)-4-oxobutanoic acid USP).
